A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in K

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy and Safety of Felzartamab in Kidney Transplant Recipients with Late Antibody-Mediated Rejection (AMR) (TRANSCEND)

Abierta

Código protocolo: 299AR301
Código EudraCT: No aplica
Grupo de investigación: Nefrología y Trasplante Renal
Servicio: Nefrología
Investigador/a principal: Bestard Matamoros, Oriol
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III